

In the claims:

Pursuant to 37 C.F.R. §1.121 the following is a complete listing of the claims of the present application:

1-33. (canceled)

34. (previously presented) A method to identify a specific binding partner compound of a phosphodiesterase polypeptide encoded by a polynucleotide selected from the group consisting of:

i) a polynucleotide encoding the polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2; and

ii) a polynucleotide that hybridizes under moderately stringent conditions to the non-coding strand of the polynucleotide of (i); said moderately stringent conditions comprising a final wash at 65° C in 2X SSC and 0.1%SDS,

said method comprising the steps of:

a) contacting the phosphodiesterase polypeptide with a compound under conditions which permit binding between the compound and the phosphodiesterase polypeptide;

b) detecting binding of the compound to the phosphodiesterase polypeptide; and

c) identifying the compound as a specific binding partner of the phosphodiesterase polypeptide.

35. (previously presented) The method according to claim 34 wherein the specific binding partner modulates activity of the phosphodiesterase polypeptide.

36. (previously presented) The method according to claim 35 wherein the compound inhibits activity of the phosphodiesterase polypeptide.

37. (previously presented) The method according to claim 35 wherein the compound enhances activity of the phosphodiesterase polypeptide.